{"id":1991,"date":"2019-06-18T17:39:41","date_gmt":"2019-06-18T15:39:41","guid":{"rendered":"https:\/\/eurecon.de\/?page_id=1991"},"modified":"2021-05-12T09:16:13","modified_gmt":"2021-05-12T07:16:13","slug":"survey-of-innovation-and-sustainability-in-pharmaceutical-companies","status":"publish","type":"page","link":"https:\/\/eurecon.de\/en\/survey-of-innovation-and-sustainability-in-pharmaceutical-companies\/","title":{"rendered":"Pharma Trend: Study on innovation and sustainability of pharmaceutical companies"},"content":{"rendered":"\n
<\/div>\n\n\n\n
\"\"
\n
\"\"<\/figure><\/div>\n\n\n\n

Pharma Trend: Study on innovation and sustainability of pharmaceutical companies<\/p>\n\n\n\n

\n
\n
\n
CONDITIONS OF PARTICIPATION<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
REPORT VOLUMES<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
PHARMA TREND RX<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
PHARMA TREND OTC<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\n
PHARMA TREND OD \/ SC<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
DIAGNOSTIC TREND<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
PHARMA TREND BIG5<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
COMMUNICATION<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n

<\/p>\n\n\n\n

This is the pharma trend<\/h2>\n\n\n\n

Pharma Trend is the benchmark study on innovation and sustainability. The study has been conducted on behalf of the magazine PharmaBarometer since 2000 in the Rx category and since 2018 also in the categories OTC, Orphan Drugs and since 2019 also in the Specialty Care category. By surveying doctors, pharmacists and patients, it forms the basis for the awards \u201cThe Golden Tablet\u00ae<\/sup>\u201d and \u201cMost Innovative Product\u00ae<\/sup>\u201d as well as the ranking \u201cPharma Trend\u00ae<\/sup> Germany\u2019s Best Pharmaceutical Companies\u201d. In 2021, the study will be expanded to include the categories \u201cDiagnostics\u201d and \u201cDigital Health\u201d. With the expansion of Pharma Trend, companies in pharmaceuticals and medical technology will be evaluated by their most important stakeholders (doctors, pharmacists and patients) on innovation and sustainability.<\/p>\n\n\n\n

Conditions of participation<\/h2>\n\n\n\n

Participation takes place by declaration of participation. It requires the order of a report volume Pharma Trend (optionally category Rx, OTC, Orphan Drugs or Specialty Care) or Diagnostics Trend (survey of laboratory physicians) in the formats \u201cRanking\u201d, \u201cBasic\u201d or \u201cStandard\u201d.<\/p>\n\n\n\n

The order of the report volume “Pharma Trend Basis”<\/strong> entitles to determine a specialist group to be surveyed. When ordering the report volume \u201cPharma Trend Standard\u201d<\/strong>, an indication for determining the most innovative product can also be specified. Ordering the report volume \u201cRanking Basis\u201d <\/strong>requires the definition of a category in which the ordering company wants to be listed in the ranking. When ordering the \u201cStandard\u201d report volume, the ordering company is also entitled to designate three out of four other companies with which it would like to receive comparative data in the benchmark. In the report volume \u201cDiagnostic Trend Basis\u201d<\/strong>, laboratory physicians are asked about the most innovative product in laboratory medicine.<\/p>\n\n\n\n

In the report band \u201cDiagnostic Trend Standard\u201d<\/strong>, an indication and also a specialist group can be named, which is asked for the most innovative product in an indication within the framework of the Pharma Trend in the categories Rx, OTC, Orphan Drugs and Specialty Care. <\/p>\n\n\n\n

Ordering of (further) indications in the categories Diagnostics & Digital Health<\/h3>\n\n\n\n

In the Diagnostics and Digital Health categories, participation can also be made by commissioning a query on the most innovative product in a specialist group and indication, provided that this specialist group is surveyed.<\/p>\n\n\n\n

Pharma Trend \/ Diagnostic Trend Europe Big5:<\/h3>\n\n\n\n

Participation takes place by ordering the Pharma Trend Europe Big5 Basis report and requires participation in the Pharma Trend or Diagnostics Trend in Germany.<\/p>\n\n\n\n

The order of report volumes decides on the implementation of the market research study. The prerequisite for carrying out the benchmark study in Germany is at least five orders of Pharma Trend or Diagnostic Trend in the Standard format or three orders of Pharma Trend or Diagnostic Trend Europe Big 5. The number of specialist groups is limited to 10 across all categories. <\/p>\n\n\n\n

Participation deadline<\/h3>\n\n\n\n

The participation deadline for the benchmark study in Germany is 28 May 2021 and 30 July 2021 for the study in Europe.<\/p>\n\n\n\n

Report volumes<\/h2>\n\n\n\n

The\u202fbasic version<\/strong>\u202fof the report contains information on the winners of the awards \u201cDie Goldene Tablette\u00ae<\/sup>\u201d (with the exception of Diagnostic Trend) and \u201cDas innovativste Produkt\u00ae<\/sup>\u201d (Most Innovative Product\u00ae<\/sup>) with reasons for the award as well as the assessment of the image and the sales force, including many data in comparison with the previous year. The\u202freport volume Standard<\/strong>\u202fadditionally contains the assessments of four other pharmaceutical\/diagnostic companies with regard to 11 aspects, i.e.: marketing and sales quality, product and service quality, innovative strength, economic efficiency, transparency, responsibility, ethical action, management quality and business success. The report volume\u202fRanking Basis\u202f<\/strong>contains the ranking of all companies included in the benchmark study. The\u202fRanking Standard<\/strong>\u202freport volume additionally contains the assessments of four other pharmaceutical\/diagnostics companies with regard to the aforementioned 11 aspects. <\/p>\n\n\n\n

The Europe Big5<\/strong> report volume contains the country-specific evaluations.<\/p>\n\n\n\n

Pharma Trend \/ Diagnostic Trend Standard:<\/td>12,300 Euro \/ 14.800 Euro<\/td><\/tr>
Pharma Trend \/ Diagnostics Trend Basis:<\/td>9,800 Euro \/ 9,800 Euro<\/td><\/tr>
Pharma Trend \/ Diagnostics Trend Ranking:<\/td>7,300 Euro \/ 10,300 Euro<\/td><\/tr>
Pharma Trend \/ Diagnostics Trend Europe Big5 Basis:<\/td>47,600.00 Euro<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The costs for the report volume Diagnostics Trend Standard among laboratory physicians include an indication that is also surveyed in another specialist group. Each additional survey per specialist group\/indication costs 2,500 euros. The costs for the inclusion of an indication in the category “Digital Health” are 2,500 euros for one specialist group.<\/p>\n\n\n\n

Discount -10% for orders placed by 30 December 2020. Discounts for orders of several subject groups\/indications and for multi-year subscription on request.<\/p>\n\n\n\n

All prices are exclusive of VAT.<\/p>\n\n\n\n

Pharma Trend Rx<\/strong><\/h2>\n\n\n\n

Since the Pharma Trend survey was launched in 2000, eighteen different specialist groups have been surveyed in Germany: allergists, general practitioners\/internists (API), dermatologists, diabetologists, gastroenterologists, gynaecologists, ear, nose and throat specialists (ENT), cardiologists, neurologists, psychiatrists, oncologists, ophthalmologists, orthopaedists, rheumatologists, paediatricians, pneumologists, pain therapists and urologists. The focus of Pharma Trend is thus on those groups of specialists who cover the major disease patterns in therapy and prophylaxis: Cardiovascular, Diabetes, CNS, Oncology and Infection.<\/p>\n\n\n\n

The implementation of the Pharma Trend is prepared for the Rx category for the following specialist groups:<\/p>\n\n\n\n

\n
\n